Author

C. Karamboulas

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:statistical model· 1

Frequent Co-Authors

L. Ailles· 2 shared A. Apostoli· 1 shared A. M. Rozeboom· 1 shared A. S. Ng· 1 shared B. Davidson· 1 shared B. Raught· 1 shared C. H. Arrowsmith· 1 shared E. Chen· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

L. Ailles

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivMar 30, 2023

PRMT1 is a critical dependency in clear cell renal cell carcinoma through its role in post-transcriptional regulation of DNA damage response genes

J. Walton, A. S. Ng, K. Arevalo…·L. Ailles

DOI 10.1038/s41467-024-52507-y

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintAug 25, 2022

Extracellular heparan 6-O-endosulfatases SULF1 and SULF2 in HNSC and other malignancies

Y. Yang, J. Ahn, N. J. Edwards…·R. Goldman

The paper investigates SULF1 and SULF2 in HNSC and other cancers, finding SULF1 is secreted by fibroblasts and negatively impacts survival early, while SULF2, from tumor cells, affects survival later, with implications for therapy.

DOI 10.1101/2022.08.25.505356

humanbulk RNA-seq

𝕏 PostBluesky